Statera Biopharma, Inc. (STAB) is a late-clinical biotherapeutics company focused on the development of innovative immunotherapies aiming at different diseases. The company’s toll-like receptor plays an important part in the innate immune system. The company’s clinical portfolio includes STAT-201for Crohn’s disease, Entolimod for hematological issues, STAT-401 for pancreatic carcinoma, and STAT-205 for COVID-19.
The price of STAB stock in the regular trading on March 8, 2022, with a gain of 5.55% was $0.58. Its price significantly increased further by 4.31% at the last check in the premarket session on March 9, 2022.
STAB: Events and Happenings
On March 08, 2022, STAB reported its revised and preliminary financials for FY ended December 31, 2021. The revenues for the period were reported to be $1.48 million and showed a gain of 100% in comparison to the same period in 2020.
On March 07, 2022, STAB updated on the recent progression of its next-generation research work building upon the activity of STAT-200 on TLRs to enhance the drug features and clinical advantage outside opioid receptors. On March 02, 2022, STAB announced STAT-205 pilot trials protocol submission to the FDA for treating post-acute COVID-19.
On February 25, 2022, STAB informed the press about the additions to its BoDs team as Satish Chandran joined the company’s new director in place of Steve Barbarick, who resigned from the position and will continue in an advisory role.
STAB: Key Financial
On November 15, 2021, STAB released its financial statement for Q3 2021 ended September 30, 2021. Some of the key aspects are below.
Revenue
Revenue of $0.23 million was recorded in Q3 2021 against nil revenue in the same quarter of 2020. The company noticed a 100% gain in revenue over the year.
EPS
A basic and diluted net loss per share of $12.7 million or $0.47 was reported in the third quarter of 2021 compared to $5.7 million, or $1.84 in the same period in 2020.
Conclusion
STAB stock dipped by 74% YTD primarily due to the economic downfall globally. The current premarket stock drive is the influence of its preliminary fourth-quarter financial statement as it reported a record revenue in the quarter. The company observed a phenomenal gain in its revenue over the yearly period.
